Johnson & Johnson will pay $700 million to settle claims that the company continued to market its talcum powder products even as evidence tied them to a heightened risk of cancer.

The US Food and Drug Administration (FDA) has granted traditional approval to Retevmo (selpercatinib) to treat patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid ...

However, sexual dysfunction varied by cancer type. Sexual dysfunction was reported in 47% of CNS tumor survivors, 27% of Hodgkin lymphoma survivors, 26% of sarcoma survivors, 21% of leukemia survivors ...

(HealthDay News) — Generation X is experiencing larger per-capita increases in cancer incidence than Baby Boomers, according to a study published in JAMA Network Open.

AACR’s latest report highlights disparities in cancer burden according to race and ethnicity, sexuality and gender identity, and residence.

A phase 2 study suggests that combining nivolumab with reirradiation may be safe and effective for patients with recurrent or second primary head and neck squamous cell carcinoma.

The FDA has accepted for priority review the new drug application for inavolisib in combination with palbociclib and fulvestrant.

(HealthDay News) — Nearly 10% of US medical visits took place via telehealth in 2021, according to a survey published in the Annals of Internal Medicine. Researchers described telehealth use using the ...

The FDA has accepted for priority review the biologics license application for zanidatamab to treat previously treated, unresectable, locally advanced, or metastatic HER2+ biliary tract cancer.

(HealthDay News) — Second tumors after chimeric antigen receptor (CAR) T-cell therapy are rare, according to a study published in The New England Journal of Medicine. Researchers examined the ...

A recent review article describes gastric cancer as a “tricky entity” for clinicians and a “global challenge” for the healthcare system. 1 The scenario in most cases is one of aggressive disease ...